Indivior Inc v. Sparsha Pharma USA Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Indivior Inc. (Delaware) and Indivior UK Limited (United Kingdom)
  • Defendant: Sparsha Pharma USA, Inc. (California)
  • Plaintiff's Counsel: Covington & Burling LLP
• Case Identification: 3:26-cv-02633, S.D. Cal., 04/24/2026
• Venue Allegations: Venue is based on the Defendant, a California corporation, allegedly residing in and having a regular and established place of business in the Southern District of California.
• Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Suboxone® sublingual film constitutes an act of patent infringement under the Hatch-Waxman Act.
• Technical Context: The technology involves orally dissolvable films for treating opioid dependence, specifically formulations containing buprenorphine (an opioid partial agonist) and naloxone (an opioid antagonist) designed to be abuse-deterrent.
• Key Procedural History: This action was triggered by Defendant's submission of ANDA No. 220812 with a Paragraph IV certification, alleging the patents-in-suit are invalid, unenforceable, or will not be infringed. Plaintiff received a notification letter on March 12, 2026, and filed this suit within the statutory 45-day window, triggering a 30-month stay of FDA approval. U.S. Patent 9,687,454 was subject to an Inter Partes Review (IPR2019-00329), which resulted in the cancellation of claims 1-5 and 7-14. U.S. Patent 11,135,216 is subject to a terminal disclaimer.

Case Timeline

Date	Event
2009-08-07	Earliest Priority Date for '454 and '216 Patents
2010-08-30	FDA approves NDA for Suboxone® sublingual film
2017-06-27	U.S. Patent 9,687,454 Issued
2021-10-05	U.S. Patent 11,135,216 Issued
2026-03-12	Plaintiff receives Defendant's Paragraph IV Notification Letter
2026-04-24	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,687,454 - Sublingual and Buccal Film Compositions

Issued June 27, 2017

The Invention Explained

• Problem Addressed: The patent family describes the potential for abuse of oral opioid treatments, such as tablets, where a patient might not ingest the drug but instead extract the active opioid agonist for parenteral abuse (e.g., injection) to achieve a "high" '216 Patent, col. 2:5-14
• The Patented Solution: The invention is a self-supporting, orally dissolvable film designed to treat narcotic dependence. The film adheres to the buccal or sublingual mucosa, making it difficult to remove once placed in the mouth '454 Patent, col. 5:12-16 Critically, the film contains a buffer system that controls the local pH. This pH control is designed to optimize the absorption of the opioid agonist (buprenorphine) while simultaneously inhibiting the absorption of the opioid antagonist (naloxone), which would otherwise block the agonist's effect '454 Patent, col. 12:10-15 '454 Patent, col. 12:49-52 The unabsorbed antagonist is swallowed and destroyed in the stomach, but remains present in the film to deter extraction and abuse '454 Patent, col. 12:41-48
• Technical Importance: This approach provides an abuse-deterrent formulation for opioid dependence therapy that is more secure than a simple tablet, by using a combination of mucoadhesion and pH-controlled differential absorption.

Key Claims at a Glance

• The complaint asserts at least dependent claim 6 Compl. ¶32
• Claim 6 depends from claim 5, which depends from claim 4, which depends from claim 1. An IPR proceeding cancelled claims 1-5 '454 Patent, IPR Certificate The complaint's assertion of a claim that depends from a series of cancelled claims raises a significant question regarding its viability.
• For context, the elements of cancelled independent claim 1 and asserted claim 6 are:
  • Claim 1 (Cancelled): An oral, self-supporting, mucoadhesive film comprising: (a) about 40 wt % to about 60 wt % of a water-soluble polymeric matrix; (b) about 2 mg to about 16 mg of buprenorphine; (c) about 0.5 mg to about 4 mg of naloxone; and (d) an acidic buffer.
  • Claim 6 (Asserted): "The film of claim 5, wherein the weight ratio of (b):(a) is about 1:3." (Claim 5 requires the ratio to be from about 1:3 to about 1:11.5).

U.S. Patent No. 11,135,216 - Sublingual and Buccal Film Compositions

Issued October 5, 2021

The Invention Explained

• Problem Addressed: As with the related '454 Patent, this patent addresses the need for an abuse-deterrent oral dosage form for opioid dependence treatment '216 Patent, col. 2:5-14
• The Patented Solution: The '216 Patent claims a mucoadhesive film containing buprenorphine and naloxone, but with greater specificity than the '454 Patent. The claims recite specific weight ratios of the active ingredients to each other and to the buffer, and further claim the specific pharmacokinetic (PK) outcome of this formulation-namely, achieving Cmax and AUC values for buprenorphine that are bioequivalent to the branded Suboxone® tablet, while simultaneously ensuring specific Cmax and AUC values for naloxone '216 Patent, claim 1 This solution codifies the precise formulation and resulting absorption profile into the claim itself.
• Technical Importance: The invention claims not just the formulation's components, but the specific, measurable in-vivo result, tying the patent protection directly to the bioequivalent performance required for a generic drug to be approved.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶54
• The essential elements of independent claim 1 include:
  • An oral, self-supporting, mucoadhesive film comprising:
  • (a) at least 25 wt % of a water-soluble polymeric matrix;
  • (b) about 2 mg to about 16 mg of buprenorphine;
  • (c) about 0.5 mg to about 4 mg of naloxone; and
  • (d) an acidic buffer;
  • wherein the weight ratio of buprenorphine to naloxone is about 4:1;
  • wherein the weight ratio of the acidic buffer to buprenorphine is from 2:1 to 1:5; and
  • wherein application of the film results in differing absorption, yielding specific Cmax and AUC ranges for both buprenorphine and naloxone.

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Sparsha's generic product," identified as a "buprenorphine hydrochloride and naloxone hydrochloride sublingual film" for which Sparsha submitted ANDA No. 220812 to the FDA Compl. ¶25

Functionality and Market Context

The complaint alleges that Sparsha's product is a generic version of Plaintiff's Suboxone® sublingual film and that the ANDA filing relies on Indivior's original New Drug Application (NDA 22-410) Compl. ¶25 Compl. ¶12 The ANDA purportedly contains data showing the generic product is bioequivalent to Suboxone® sublingual film Compl. ¶25 The specific technical details of the accused product's formulation are not public, as the complaint notes that this information is confidential and was provided to the Plaintiff under an Offer of Confidential Access Compl. ¶26 Infringement is alleged based on Plaintiff's review of excerpts from the ANDA Compl. ¶26

IV. Analysis of Infringement Allegations

The complaint does not provide claim charts or detailed technical mappings. The analysis below is based on the complaint's narrative allegations that the accused generic product infringes the asserted claims Compl. ¶32 Compl. ¶54 and is bioequivalent to the branded product Compl. ¶25

No probative visual evidence provided in complaint.

'454 Patent Infringement Allegations

Claim Element (from dependent Claim 6)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
An oral, self-supporting, mucoadhesive film...	The complaint alleges Sparsha's generic product is a sublingual film intended for oral use.	¶25	col. 5:12-16
comprising: (a) about 40 wt % to about 60 wt % of a water-soluble polymeric matrix	The complaint alleges Sparsha's ANDA product infringes, suggesting it contains a polymeric matrix within this weight range.	¶32	col. 5:54-6:3
(b) about 2 mg to about 16 mg of buprenorphine...	The complaint suggests the accused product contains a dosage of buprenorphine, as it is a generic version of Suboxone®.	¶25	col. 13:13-16
(c) about 0.5 mg to about 4 mg of naloxone...	The complaint suggests the accused product contains a dosage of naloxone, as it is a generic version of Suboxone®.	¶25	col. 13:20-22
(d) an acidic buffer	The complaint alleges infringement, suggesting the presence of a buffer to control absorption, a key feature of the Suboxone® film.	¶32	col. 12:10-15
wherein the weight ratio of (b):(a) is about 1:3	The complaint's allegation that claim 6 is infringed suggests the accused product meets this specific ratio of buprenorphine to polymer matrix.	¶32	col. 24:7-8

'216 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
An oral, self-supporting, mucoadhesive film comprising: (a) at least 25 wt % of a water-soluble polymeric matrix...	The complaint alleges Sparsha's product is a sublingual film, which implies it is a mucoadhesive film comprising a polymeric matrix.	¶25	col. 5:17-24
(b) about 2 mg to about 16 mg of buprenorphine... and (c) about 0.5 mg to about 4 mg of naloxone... wherein the weight ratio of (b):(c) is about 4:1	The complaint identifies the accused product as a buprenorphine and naloxone film, and the 4:1 ratio is standard for Suboxone®.	¶25	col. 1:24-30
(d) an acidic buffer... wherein the weight ratio of (d):(b) is from 2:1 to 1:5	The allegation of infringement suggests the accused product contains a buffer system meeting this specific ratio relative to buprenorphine.	¶54	col. 1:31-33
wherein application of the film... results in differing absorption between buprenorphine and naloxone, with a buprenorphine Cmax from about 0.624 ng/ml to about 5.638 ng/ml... and a naloxone Cmax from about 41.04 pg/ml to about 323.75 pg/ml...	The complaint alleges Sparsha's ANDA "purports to contain data showing bioequivalence," which directly supports the allegation that the product meets the claimed pharmacokinetic parameters.	¶25	col. 1:34-45

• Identified Points of Contention:
  • Legal Question ('454 Patent): A threshold issue is whether claim 6 of the '454 Patent is legally assertable. The IPR certificate shows that independent claim 1 and all intermediate dependent claims (2-5) from which claim 6 depends have been cancelled. This raises a significant question as to whether claim 6 remains valid and enforceable.
  • Technical/Factual Question ('216 Patent): The infringement analysis for the '216 Patent may focus on strict compliance with the quantitative limitations. The dispute could center on whether the accused product's formulation, as detailed in its ANDA, falls within the claimed weight ratios (e.g., "about 4:1") and, critically, whether its bioequivalence data demonstrates achievement of the specific Cmax and AUC ranges recited in claim 1.

V. Key Claim Terms for Construction

• The Term: "acidic buffer" (from '454 Patent, claim 1; '216 Patent, claim 1)
• Context and Importance: This term is the technological core of the invention, as the buffer is what allegedly enables the differential absorption of the agonist and antagonist. The definition of this term is critical for determining infringement, especially for the ratio requirement in claim 1 of the '216 patent (weight ratio of buffer to buprenorphine). Practitioners may focus on this term because its scope will determine whether a wide range of pH-controlling agents infringe or only a narrow set.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification describes the function of the buffer as controlling the "local pH" to optimize absorption of one active while inhibiting another '454 Patent, col. 12:10-20 This functional language may support an interpretation that any agent or system achieving this pH control constitutes an "acidic buffer."
  • Evidence for a Narrower Interpretation: The patents repeatedly provide specific examples, stating "the buffer may include sodium citrate, citric acid, and combinations thereof" '454 Patent, col. 13:42-45 A defendant may argue that the term should be limited to these specific exemplified chemicals or similar citrate-based systems, rather than any substance that can modulate pH.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon approval, Sparsha's commercial activities and marketing will actively induce infringement by end-users and medical professionals, presumably through product labeling and instructions for use Compl. ¶36 Compl. ¶58
• Willful Infringement: The complaint alleges that Sparsha had actual, pre-suit knowledge of the patents-in-suit prior to filing its ANDA, and was aware that the submission constituted an act of infringement Compl. ¶38 Compl. ¶60 This allegation is based on the statutory requirement for Sparsha to send a Paragraph IV certification notice identifying the patents covering the branded drug.

VII. Analyst's Conclusion: Key Questions for the Case

1. A threshold legal question of patent validity: Can claim 6 of the '454 patent be asserted, or is it invalid as a matter of law because all claims in its dependency chain (claims 1-5) were cancelled in a prior Inter Partes Review?
2. A central factual question of quantitative infringement: Does the formulation and bioequivalence data in Sparsha's confidential ANDA demonstrate that its proposed generic film meets the specific weight ratio and pharmacokinetic limitations recited in claim 1 of the '216 patent, or are there material differences in composition or performance?
3. A key claim construction question of definitional scope: What is the proper construction of "acidic buffer"? Is it defined functionally by its ability to create a specific local pH environment, or is it limited to the citrate-based chemical systems explicitly described in the patent's examples? The answer will determine the scope of equivalents and the method for calculating the buffer-to-agonist weight ratio.